PD-1抑制剂对非小细胞肺癌患者Mito+ T淋巴细胞免疫代谢影响模式
Effect Model of PD-1 Inhibitors on Immune Metabolism of Mito+ T Lymphocytes in Patients with Non-Small Cell Lung Cancer
DOI: 10.12677/ACM.2023.131145, PDF,   
作者: 王 铮*：青岛大学医学部，山东 青岛；陈存海, 马学真#：青岛大学附属青岛市中心医院，山东 青岛
关键词: 非小细胞肺癌；免疫治疗；T淋巴细胞；免疫代谢；Non-Small Cell Lung Cancer； Immunotherapy； T Lymphocytes； Immune Metabolism
摘要: 目的：探究PD-1抑制剂对非小细胞肺癌患者Mito+ T淋巴细胞免疫代谢影响模式。方法：选取在2020-07-01至2022-08-01在青岛市中心医院接受II线单药应用免疫治疗(替雷利珠单抗200 mg q3w)的70例NSCLC癌症患者作为观察组，以及50例体健的志愿者作为对照组。利用Mito-Tracker，通过流式细胞术探究非小细胞肺癌患者T淋巴细胞免疫代谢变化，以及应用替雷利珠单抗探究对非小细胞肺癌患者T淋巴细胞免疫代谢影响模式。结果：非小细胞肺癌患者Mito+ CD3+、Mito+ CD3+ CD4+、Mito+ CD3+ CD8+计数较健康人均明显下降，差距具有统计学意义(p < 0.05)。经PD-1抑制剂治疗4周期后，T淋巴细胞线粒体损伤阳性的观察组患者Mito+ CD3+、Mito+ CD3+ CD4+、Mito+ CD3+ CD8+计数较治疗前差异无统计学意义，T淋巴细胞线粒体损伤阴性的观察组患者则较治疗前明显提高(p < 0.05)，且通过应用Logistic回归对多因素分析并绘制ROC曲线，发现T淋巴细胞线粒体损伤阴性组患者Mito+ CD3+、Mito+ CD3+ CD4+、Mito+ CD3+ CD8+计数对免疫治疗疗效具有一定的预测作用。结论：PD-1抑制剂可以在一定程度上调节非小细胞肺癌患者较健康人群受损的淋巴细胞亚群，而T淋巴细胞线粒体损伤指数阴性患者拥有更佳临床受益。
Abstract: Objective: To explore the effect model of PD-1 inhibitor on the immune metabolism of Mito+ T lym-phocytes in patients with non-small cell lung cancer. Methods: From July 1, 2020 to August 1, 2022, 70 NSCLC cancer patients who received second-line single drug immunotherapy (Tirelizumab 200 mg q3w) in Qingdao Central Hospital were selected as the observation group, and 50 healthy vol-unteers as the control group. Mito-Tracker was used to investigate the changes of T lymphocyte immune metabolism in patients with non-small cell lung cancer by flow cytometry, and the effect of tirelizumab on T lymphocyte immune metabolism in patients with non-small cell lung cancer. Re-sults: The Mito+ CD3+, Mito+ CD3+ CD4+, Mito+ CD3+ CD8+ counts in NSCLC patients were signifi-cantly lower than those in healthy people (p < 0.05). After 4 cycles of PD-1 inhibitor treatment, the Mito+ CD3+, Mito+ CD3+ CD4+, Mito+ CD3+ CD8+ counts in the observation group with positive T lymphocyte mitochondrial damage had no significant difference compared with those before treat-ment, while those in the observation group with negative T lymphocyte mitochondrial damage were significantly higher than those before treatment (p < 0.05). By using logistic regression to analyze multiple factors and draw ROC curve, it was found that Mito+ CD3+, Mito+ CD3+ CD4+ and Mito+ CD3+ CD8+ counts can predict the efficacy of immunotherapy. Conclusion: PD-1 inhibitor can regu-late the damaged lymphocyte subsets in NSCLC patients to a certain extent, and the patients with negative T lymphocyte mitochondrial damage index have better clinical benefits.
文章引用：王铮, 陈存海, 马学真. PD-1抑制剂对非小细胞肺癌患者Mito+ T淋巴细胞免疫代谢影响模式[J]. 临床医学进展, 2023, 13(1): 1038-1047. https://doi.org/10.12677/ACM.2023.131145

参考文献

[1] 国家卫生健康委办公厅. 原发性肺癌诊疗指南(2022年版) [J]. 协和医学杂志, 2022, 13(4): 549-570.
https://xhyxzz.pumch.cn/cn/article/doi/10.12290/xhyxzz.2022-0352
[2] Schalper, K.A., et al. (2015) Objective Measurement and Clinical Significance of TILs in Non-Small Cell Lung Cancer. Journal of the National Cancer Institute, 107, dju435. [Google Scholar] [CrossRef] [PubMed]
[3] Mu, C.-Y., et al. (2011) High Expression of PD-L1 in Lung Cancer May Contribute to Poor Prognosis and Tumor Cells Immune Escape through Suppressing Tumor Infiltrating Dendritic Cells Maturation. Medical Oncology, 28, 682-688. [Google Scholar] [CrossRef] [PubMed]
[4] Brahmer, J.R. and Pardoll, D.M. (2013) Immune Checkpoint In-hibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer. Cancer Immunology Research, 1, 85-91. [Google Scholar] [CrossRef] 
[5] Wang, J., et al. (2021) Tislelizumab plus Chemotherapy vs Chemotherapy Alone as First-Line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Ran-domized Clinical Trial. JAMA Oncology, 7, 709-717. [Google Scholar] [CrossRef] [PubMed]
[6] Clutton, G., et al. (2019) A Reproducible, Objective Method Using MitoTracker Fluorescent Dyes to Assess Mitochondrial Mass in T Cells by Flow Cytometry. Cytometry Part A, 95, 450-456. [Google Scholar] [CrossRef] [PubMed]
[7] Newell, E.W. and Becht, E. (2018) High-Dimensional Pro-filing of Tumor-Specific Immune Responses: Asking T Cells about What They “See” in Cancer. Cancer Immunology Research, 6, 2-9. [Google Scholar] [CrossRef] 
[8] Hanson, H.L., Kang, S.S., Norian, L.A., et al. (2004) CD4-Directed Peptide Vaccination Augments an Antitumor Response, but Efficacy Is Limited by the Number of CD8+ T Cell Precursors. The Journal of Immunology, 172, 4215-4224. [Google Scholar] [CrossRef] [PubMed]
[9] Knutson, K.L. and Disis, M.L. (2005) Tumor Antigen-Specific T Helper Cells in Cancer Immunity and Immunotherapy. Cancer Immunology, Immunotherapy, 54, 721-728. [Google Scholar] [CrossRef] [PubMed]
[10] Bossi, G., Trambas, C., Booth, S., et al. (2002) The Secretory Synapse: The Secrets of a Serial Killer. Immunological Reviews, 189, 152-160. [Google Scholar] [CrossRef] 
[11] Preusser, M., Berghoff, A.S., Thallinger, C. and Zielinski, C.C. (2016) Cancer Immune Cycle: A Video Introduction to the Interaction between Cancer and the Immune System. ESMO Open, 1, e000056. [Google Scholar] [CrossRef] [PubMed]
[12] Junttila, M.R. and de Sauvage, F.J. (2013) Influence of Tu-mour Micro-Environment Heterogeneity on Therapeutic Response. Nature, 501, 346-354. [Google Scholar] [CrossRef] [PubMed]
[13] Scharping, N.E., et al. (2016) The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction. Immunity, 45, 374-388. [Google Scholar] [CrossRef] [PubMed]
[14] MacIver, N.J., Michalek, R.D. and Rathmell, J.C. (2013) Met-abolic Regulation of T Lymphocytes. Annual Review of Immunology, 31, 259-283. [Google Scholar] [CrossRef] [PubMed]
[15] Vardhana, S.A., Hwee, M.A., Berisa, M., et al. (2020) Impaired Mitochondrial Oxidative Phosphorylation Limits the Self-Renewal of T Cells Exposed to Persistent An-tigen. Nature Immunology, 21, 1022-1033. [Google Scholar] [CrossRef] [PubMed]
[16] Patsoukis, N., Weaver, J.D., Strauss, L., et al. (2017) Im-munometabolic Regulations Mediated by Coinhibitory Receptors and Their Impact on T Cell Immune Responses. Fron-tiers in Immunology, 8, Article No. 330. [Google Scholar] [CrossRef] [PubMed]
[17] Chamoto, K., Chowdhury, P.S., Kumar, A., et al. (2017) Mito-chondrial Activation Chemicals Synergize with Surface Receptor PD-1 Blockade for T Cell-Dependent Antitumor Activ-ity. Proceedings of the National Academy of Sciences of the United States of America, 114, E761-E770. [Google Scholar] [CrossRef] [PubMed]
[18] Farkona, S., Diamandis, E.P. and Blasutig, I.M. (2016) Cancer Im-munotherapy: The Beginning of the End of Cancer? BMC Medicine, 14, 73. [Google Scholar] [CrossRef] [PubMed]
[19] Dronca, R.S., Liu, X., Harrington, S.M., et al. (2016) T Cell Bim Levels Reflect Responses to Anti-PD-1 Cancer Therapy. JCI Insight, 1, e86014. [Google Scholar] [CrossRef] [PubMed]
[20] Munari, E., Zamboni, G., Lunardi, G., et al. (2018) PD-L1 Expres-sion Heterogeneity in Non-Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections. Journal of Thoracic Oncology, 13, 1113-1120. [Google Scholar] [CrossRef] [PubMed]
[21] Lisberg, A. and Garon, E.B. (2016) The Value of PD-L1 Testing in Non-Small-Cell Lung Cancer. JAMA Oncology, 2, 571-572. [Google Scholar] [CrossRef] [PubMed]
[22] Proto, C., Ferrara, R., Signorelli, D., et al. (2019) Choosing Wisely First Line Immunotherapy in Non-Small Cell Lung Cancer (NSCLC): What to Add and What to Leave Out. Cancer Treatment Reviews, 75, 39-51. [Google Scholar] [CrossRef] [PubMed]
[23] Ghoneim, H.E., Fan, Y., Moustaki, A., et al. (2017) De Novo Epi-genetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation. Cell, 170, 142-157.e19. [Google Scholar] [CrossRef] [PubMed]

为你推荐